Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Guardant Health (NASDAQ:GH) had its price target hoisted by analysts at Stifel Nicolaus from $53.00 to $60.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 28.07% from the company’s previous close.

GH has been the subject of a number of other research reports. Mizuho initiated coverage on Guardant Health in a research note on Thursday, April 10th. They set an “outperform” rating and a $55.00 price objective for the company. Raymond James reiterated an “outperform” rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Barclays dropped their price objective on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group boosted their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group raised their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $51.64.

Guardant Health Stock Down 4.1 %

Guardant Health stock opened at $46.85 on Thursday. The stock has a 50-day moving average price of $43.74 and a 200 day moving average price of $38.12. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of -13.16 and a beta of 1.45. Guardant Health has a 52 week low of $18.01 and a 52 week high of $52.92.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to analysts’ expectations of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.46) EPS. Research analysts anticipate that Guardant Health will post -2.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of GH. R Squared Ltd purchased a new position in Guardant Health during the fourth quarter worth approximately $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the 4th quarter worth $43,000. Kimelman & Baird LLC acquired a new position in shares of Guardant Health during the 4th quarter valued at about $58,000. NewEdge Advisors LLC grew its holdings in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after purchasing an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health during the fourth quarter worth about $61,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.